Publications by authors named "S Servitja"
Background: Prognostic factors for ambulatory oncology patients have been described, including Eastern Cooperative Oncology Group (ECOG), tumor stage and malnutrition. However, there is no firm evidence on which variables best predict mortality in hospitalized patients receiving active systemic treatment. Our main goal was to develop a predictive model for 90-day mortality upon admission.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess the effectiveness of olaparib in patients with advanced triple negative breast cancer who have homologous recombination deficiency but do not have BRCA1/2 mutations.
- The NOBROLA trial was conducted as a phase IIa study, enrolling patients treated with olaparib, and focused on the clinical benefit rate as the main measurement.
- Out of 114 patients screened, only 6 were eligible; the median follow-up was 8.5 months, showing a clinical benefit rate of 50%, suggesting potential for further research.
Gestational breast cancer: distinctive molecular and clinico-epidemiological features.
J Mammary Gland Biol Neoplasia
November 2024
Gestational breast cancer (GBC), defined as breast cancer (BC) diagnosed during pregnancy or the first-year post-partum, accounts for 6-15% of BC cases in women aged 20-44 years. GBC has worse prognosis than non-GBC, but reasons behind are not clear. The GEICAM/2012-03 Study (Molecular Characterization of Gestational Breast Cancer) is a multicenter prospective/retrospective observational registry of patients diagnosed with GBC.
View Article and Find Full Text PDFBackground: Trastuzumab deruxtecan (T-DXd) is approved for human epidermal growth factor receptor 2 (HER2)-positive and HER2-low advanced breast cancer (ABC). T-DXd has shown encouraging intracranial activity in HER2-positive ABC patients with stable or active brain metastases (BMs); however, its efficacy in patients with HER2-low ABC with BMs is not well established yet.
Methods: DEBBRAH is a single-arm, five-cohort, phase II study evaluating T-DXd in patients with central nervous system involvement from HER2-positive and HER2-low ABC.
Article Synopsis
- RAD51C and RAD51D genes play a crucial role in DNA repair, and mutations in these genes significantly increase the risk of developing ovarian and breast cancer.
- This study analyzed the clinical characteristics of 91 patients and 90 relatives with pathogenic variants in RAD51C/D across multiple Spanish hospitals, focusing on their tumors' homologous recombination deficiency (HRD) status.
- Findings showed that a substantial portion of the carriers were women, with a high incidence of breast and ovarian cancer; the study also determined the prevalence of HRD in untreated tumors from these patients.